Cyclobutyl purine derivative, angiogenesis promoting agent, lumen formation promoting agent, neurocyte growth promoting agent, and drug

Patent metadata

Field	Value
Publication number	US-9273050-B2
Application number	US-200913130952-A
Country	US
Kind code	B2
Filing date	Nov 27, 2009
Priority date	Nov 27, 2008
Publication date	Mar 1, 2016
Grant date	Mar 1, 2016

Abstract

Provided is a compound having at least one selected from the group consisting of cell growth promoting activity, angiogenesis promoting activity, lumen formation promoting activity, cell migration promoting activity, and neurocyte growth promoting activity, which is a chemically stable low-molecular-weight substance that has high absorbability and can be supplied stably at a low cost because of its low molecular weight. A cyclobutyl purine derivative, a tautomer or stereoisomer thereof, or a salt, solvate, or hydrate thereof according to the present invention is a cyclobutyl purine derivative represented by the following general formula (1), a tautomer or stereoisomer thereof, or a salt, solvate, or hydrate thereof.

First claim

The invention claimed is:

1. A cyclobutyl purine derivative represented by the following formula (1), a tautomer or a stereoisomer thereof, or a salt thereof:

where:
X 1 is chlorine;
X 2 is NH 2 ;
X 3 is a hydrogen atom; and
each of R 1 and R 2 is C 2 OH.

2. The cyclobutyl purine derivative according to claim 1 , the tautomer or the stereoisomer thereof, or the salt thereof, which is 6-amino-2-chloro-9-[trans-trans-2,3-bis(hydroxymethyl)cyclobutyl]purine a tautomer or a stereoisomer thereof, or a salt, a solvate, or a hydrate thereof.

3. A promoting agent having at least one function selected from the group consisting of an angiogenesis-promoting function, a lumen formation-promoting function, and a neurocyte growth-promoting function, the promoting agent comprising:
a cyclobutyl purine derivative that is represented by following formula (1′), a tautomer or a stereoisomer thereof, or a salt thereof:

where:
X 1 ′ is chlorine;
X 2 ′ is NH 2 ;
X 3 ′ is a hydrogen atom; and
each of R 1 ′ and R 2 ′ is CH 2 OH.

4. A promoting agent having at least one function selected from the group consisting of an angiogenesis-promoting function, a lumen formation-promoting function, and a neurocyte growth-promoting function, the promoting agent comprising:
the cyclobutyl purine derivative according to claim 2 , the tautomer or the stereoisomer thereof, or the salt thereof.

5. A drug having at least one function selected from the group consisting of promoting angiogenesis, promoting lumen formation, and promoting neurocyte growth, the drug comprising:
at least one compound selected from the group consisting of the cyclobutyl purine derivative according to claim 3 , the tautomers and the stereoisomers thereof, the salts thereof and
at least, one pharmaceutically acceptable additive.

Assignees

• Tsukamoto Ikuko
• Konishi Ryoji
• Tokuda Masaaki
• Kubota Yasuo
• Maruyama Tokumi
• Kosaka Hiroaki
• Igarashi Junsuke
• Univ Kagawa Nat Univ Corp

Inventors

• Tsukamoto Ikuko
• Konishi Ryoji
• Tokuda Masaaki
• Kubota Yasuo
• Maruyama Tokumi
• Kosaka Hiroaki
• Igarashi Junsuke

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title